|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fatty liver disease,an emerging etiology of hepatocellular carcinoma in Argentina显示文摘AIM To investigate any changing trends in the etiologies of hepatocellular carcinoma(HCC) in Argentina during the last years. METHODS A longitudinal cohort study was conducted by 14 regional hospitals starting in 2009 through 2016. All adult patients with newly diagnosed HCC either with pathology or imaging criteria were included. Patients were classified as presenting non-alcoholic fatty liver disease(NAFLD) either by histology or clinically, provided that all other etiologies of liver disease were ruled out, fatty liver was present on abdominal ultrasound and alcohol consumption was excluded. Complete follow-up was assessed in all included subjects since the date of HCC diagnosis until death or last medical visit.RESULTS A total of 708 consecutive adults with HCC were included. Six out of 14 hospitals were liver transplant centers(n = 484). The prevalence of diabetes mellitus was 27.7%. Overall, HCV was the main cause of liver disease related with HCC(37%) including cirrhotic and non-cirrhotic patients, followed by alcoholic liver disease 20.8%, NAFLD 11.4%, cryptogenic 9.6%, HBV 5.4% infection, cholestatic disease and autoimmune hepatitis 2.2%, and other causes 9.9%. A 6-fold increase in the percentage corresponding to NAFLDHCC was detected when the starting year, i.e., 2009 was compared to the last one, i.e., 2015(4.3% vs 25.6%; P < 0.0001). Accordingly, a higher prevalence of diabetes mellitus was present in NAFLD-HCC group 61.7% when compared to other than NAFLD-HCC 23.3%(P < 0.0001). Lower median AFP values at HCC diagnosis were observed between NAFLD-HCC and non-NAFLD groups(6.6 ng/m L vs 26 ng/m L; P = 0.02). Neither NAFLD nor other HCC etiologies were associated with higher mortality.CONCLUSION The growing incidence of NAFLD-HCC documented in the United States and Europe is also observed in Argentina, a confirmation with important Public Health implications. | Federico Pinero Josefina Pages Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Manuel Cobos Carlos Rosales Gustavo Romero Lucas McCormack Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2018 | World Journal of Hepatology2018，10，1： | 4 |
| 2 | Intermediate-advanced hepatocellular carcinoma in Argentina:Treatment and survival analysis显示文摘BACKGROUND Hepatocellular carcinoma(HCC) represents the sixteenth most frequent cancer in Argentina. The rise of new therapeutic modalities in intermediate-advanced HCC opens up a new paradigm for the treatment of HCC.AIM To describe real-life treatments performed in patients with intermediateadvanced HCC before the approval of new systemic options.METHODS This longitudinal observational cohort study was conducted between 2009 and2016 in 14 different regional hospitals from Argentina. Included subjects had intermediate-advanced Barcelona Clinic Liver Cancer(BCLC) HCC stages(BCLC B to D). Primary end point analyzed was survival, which was assessed for each BCLC stage from the date of treatment until last patient follow-up or death.Kaplan Meier survival curves and Cox regression analysis were performed, with hazard ratios(HR) calculations and 95% confidence intervals(95%CI).RESULTS From 327 HCC patients, 41% were BCLC stage B, 20% stage C and 39% stage D.Corresponding median survival were 15 mo(IQR 5-26 mo), 5 mo(IQR 2-13 mo)and 3 mo(IQR 1-13 mo)(P < 0.0001), respectively. Among BCLC-B patients(n =135), 57% received TACE with a median number of 2 sessions(IQR 1-3 sessions).Survival was significantly better in BCLC-B patients treated with TACE HR =0.29(CI: 0.21-0.40) than those without TACE. After tumor reassessment by RECIST 1.1 criteria following the first TACE, patients with complete response achieved longer survival (HR = 0.15(CI: 0.04-0.56, P = 0.005))Eighty-two patients were treated with sorafenib, mostly BCLC-B and C(87.8%). However,12.2% were BCLC-D. Median survival with sorafenib was 4.5 mo(IQR 2.3-11.7 mo);which was lower among BCLC-D patients 3.2 mo(IQR 2.0-14.1 mo). A total of 36 BCLC-B patients presented tumor progression after TACE. In these patients,treatment with sorafenib presented better survival when compared to those patients who received sorafenib without prior TACE [HR = 0.26(CI: 0.09-0.71);P= 0.013].CONCLUSION In this real setting, our results were lower than expected. This highlights unmet needs in Argentina, prior to the introduction of new treatments for HCC. | Federico Pinero Sebastián Marciano Nora Fernández Jorge Silva Margarita Anders Alina Zerega Ezequiel Ridruejo Gustavo Romero Beatriz Ameigeiras Claudia D’Amico Luis Gaite Carla Bermúdez Virginia Reggiardo Luis Colombato Adrián Gadano Marcelo Silva | 2019 | World Journal of Gastroenterology2019，25，27： | 3 |
| 3 | Fucoidans from the brown seaweed Adenocystis utricularis: extraction methods, antiviral activity and structural studies显示文摘 | Nora M A P Carlos A P Elsa B D | 2003 | Carbohyd Res2003，338，2： | 1 |
| 4 | Ion range estimation by using dual energy computed tomography显示文摘 | Nora H Bemhard K Julien D | 2013 | Zeitschrift far Medizinische Physik2013，23，4： | 1 |
| 5 | Uhrastaging of early colon cancer using lymphatic mapping and molecular analysis显示文摘 | Bilchik A J Nora D Tollenaar RA | 2002 | Eur J Cancer2002，38，7： | 1 |
| 6 | Protein kinase Cθ(PKCθ)expression and constitutive activation in gastrointestinal stromal tumors(GISTs)显示文摘 | Anette D Nora EJ Fabiola M | 2004 | Cancer Res2004，64，： | 1 |
| 7 | Sentinel lymph node mapping in colorectal cancer显示文摘 | Saha S Nora D Wong JH | 2000 | Surg Clin North Am2000，80，6： | 1 |
| 8 | Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human Brain 显示文摘 | Nora D Volkow MD Joanna S | 2009 | JAMA2009，301，11： | 1 |
| 9 | Sentinel lymph node mapping in colorectal cancer-a review显示文摘 | Saha S Nora D Wong JH | 2000 | Surg Clin North Am2000，80，： | 1 |
| 10 | Sentinel lymph node mapping in colorectal cancer -a review 显示文摘 | Saha S Nora D Wong JH | 2000 | Surg Clin North Am2000，80，6： | 1 |
| 11 | Linear equalisers with dynamic and automatic length selection显示文摘 | RIERO-PALOU F NORAS J M CRUICKSHANK D J M | 2001 | Electron Letters2001，37，25： | 1 |
| 12 | Determinants of c- are giving burden and quality of life in caregivers of stroke pa- tients显示文摘 | Emily McCullagh Gavin B Nora D | 2005 | Stroke2005，36，： | 1 |
| 13 | Hypocalcemic myop- athy without tetany due to idiopathic hypoparathyroidism: case report 显示文摘 | Nora DB Fricke D Becker J | 2004 | Arq Neuropsiquiatr2004，62，： | 1 |
| 14 | Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis 显示文摘 | Bilchik AJ Nora D Tollenaar RA | 2002 | Eur J Cancer2002，38，7： | 1 |
| 15 | Sentinel lymph node mapping in colorectal carcinoma: a review 显示文摘 | Saha S Nora D Wong JH | 2000 | Surg Clin North Am2000，80，6： | 1 |
| 16 | Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis 显示文摘 | Bilchik A J Nora D Tollenaar RA | 2002 | Eur J Cancer2002，38，7： | 1 |
| 17 | Sentinel lymph node mapping in colorectal cancer:a review 显示文摘 | Saha S Nora D Wong JH | 2000 | Surg Clin North Am2000，80，6： | 1 |
| 18 | Sentinel lymph node mappong in colo-rectal cancer 显示文摘 | Saha S Nora D Wong JH | 2000 | Surg Clin North Am2000，80，6： | 1 |
| 19 | Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis显示文摘 | Bilchik A J Nora D Tollenaar R A | 2002 | Eur J Cancer2002，38，7： | 1 |
| 20 | Linear equalizers with dynamic and automatic length selection显示文摘 | Riero-Palou F Noras J M Cruickshank D G M | 2001 | Electron Lett2001，37，25： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员